JAMES M. BACKES, PHARM.D. Curriculum Vitaeprovost.ku.edu/.../files/docs/candidate-cvs/backes-resume.pdf · 2016 – Present: Associate Dean for Clinical and Medical Center Affairs

JAMES M. BACKES, PHARM.D. Curriculum Vitae

Personal Information

Professional Address: University of Kansas Medical Center MS 4047; 3901 Rainbow Blvd. The University of Kansas Hospital Kansas City, KS 66160 Email Address: [email protected] Office Phone: (913) 588-5324

Current Position 2016 – Present: Associate Dean for Clinical and Medical Center Affairs University of Kansas Medical Center Campus University of Kansas School of Pharmacy Education 1992 - 1993: Pharm.D.

Creighton University School of Pharmacy, Omaha, NE

1988 - 1991: B.S. Pharmacy Creighton University School of Pharmacy, Omaha, NE

1986 - 1988: Pre-Pharmacy, 1988

Northeast Community College, Norfolk, NE Professional Licensure 1998 – Present: Pharmacist Licensure: Kansas 1-13009 1991 – Present: Pharmacist Licensure: Nebraska 10479 (inactive status) Academic Rank and Clinical Administrative Positions 2014 – Present: Professor Pharmacy Practice Department University of Kansas School of Pharmacy Lawrence, KS 66047 2014 – Present: Professor (adjunct appointment) Department of Internal Medicine University of Kansas School of Medicine Kansas City, KS 66160 2006 – Present: Assistant Director Atherosclerosis and LDL-Apheresis Center Internal Medicine Department – Division of Clinical Pharmacology University of Kansas School of Medicine Kansas City, KS 66160

James M. Backes, Pharm.D. 2

2009 - 2014: Associate Professor Pharmacy Practice Department University of Kansas School of Pharmacy Lawrence, KS 66047 2009 – 2014: Associate Professor (adjunct appointment) Department of Internal Medicine University of Kansas School of Medicine Kansas City, KS 66160 2007 - 2009: Clinical Associate Professor Pharmacy Practice Department University of Kansas School of Pharmacy Lawrence, KS 66047 2007 – 2009: Clinical Associate Professor (adjunct appointment) Department of Internal Medicine University of Kansas School of Medicine Kansas City, KS 66160 2006 – 2007: Clinical Assistant Professor (adjunct appointment) Department of Internal Medicine University of Kansas School of Medicine Kansas City, KS 66160 1998 - 2007: Clinical Assistant Professor Pharmacy Practice Department University of Kansas School of Pharmacy Lawrence, KS 66047 1995 - 1998: Adjunct Clinical Assistant Professor Pharmacy Practice Department University of Nebraska College of Pharmacy Omaha, NE 68198 Clinical Practice 1998 - Present: Clinical Pharmacist Atherosclerosis and LDL-Apheresis Center

Clinical focus: managing patients with complex dyslipidemia and other metabolic conditions (e.g. hypertension, diabetes mellitus, hypothyroidism). Clinical schedule: Monday and Thursday Annual patient visits: ~1500 (1250 ‘follow-up’/250 ‘new’)

1998 - 2009: Clinical Pharmacist Comprehensive Epilepsy Center

Clinical focus: managing patients with complex seizure disorders/syndromes Clinical schedule: Monday, Wednesday, and Friday Annual patient visits: ~1200


Professional Experience 2002 – Present: Relief (staff/clinical) Pharmacist – Inpatient Pharmacy Menorah Medical Center

Overland Park, KS 66209

1999 – 2002: Relief (staff) Pharmacist Eckerd Drug

Overland Park, KS 66207 1995 – 1998: Clinical Pharmacist Family Medicine Clinic University of Nebraska Medical Center

Omaha, NE 68198 1994 – 1996: Staff Pharmacist Outpatient Pharmacy University of Nebraska Medical Center

Omaha, NE 68198 1992 – 1998: Staff Inpatient Pharmacist Nebraska Methodist Hospital

Omaha, NE 68198 1991 – 1995: Staff Senior Pharmacist Shopko Pharmacy

Norfolk, NE 68701 Honors and Awards

• Senior Administrative Fellowship, KU - Lawrence (Office of Faculty Development) (2016 - 2017) • First Place Poster Award - Encore Poster Presentation, Kansas Council of Health-System

Pharmacist Annual Meeting, Lawrence, KS (2011) “Evaluation of associations between body mass index and serum vitamin D levels”.

• Rho Chi Teaching Award (2010) • Selected to the 2010 Focused Investigator Training (FIT) Program, Tucson, AZ (2010) • Best Research Poster, Kansas Public Health Conference, Topeka, KS (2008) “Diabetes Care

Quality for Kansans with Physical & Developmental Disabilities” • Finalist Best Poster Competition – 2nd runner up, American College of Clinical Pharmacy Spring

Meeting, Phoenix, AZ (2008) “Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance”.

• Preceptor of the Year, University of Kansas School of Pharmacy (2008) • Who's Who in Medicine and Healthcare, 2006-2007, 6th Edition (2006 - 2007) • Department Excellence in Teaching Award, KU Center of Teaching Excellence (2005) • Preceptor of the Year, University of Kansas School of Pharmacy (2001) • Preceptor of the Year, University of Kansas School of Pharmacy (2000)


Research/Scholarly Work Publications (Peer-reviewed/refereed)

Book Chapters

1. Moriarty, P. M., Gibson, C. A., & Backes, J. M. (2008). Clinical Challenges in Lipid Disorders.

What is familial hypercholesterolemia and how should it be treated? United Kingdom: Clinical Publishing of Oxford.

Journal Articles

1. Backes, J. M., Melton B. L., Ruisinger, J. F., Burkhardt C. D., & Moriarty, P. M. (2019).

Comparing Patients’ Prescribed, Self-Reported, and Actual Intake of Supplemental eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA). J Clin Lipidol, 13: 170-75.

2. Funk, R. S., Singh, R. K., Winefield, R. D., Kandel, S. E., Ruisinger, J. F., Moriarty, P. M.,

Backes, J. M. (2017). Variability in Potency Among Commercial Preparations of Berberine. J Diet Suppl, 15: 343-51.

3. Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2017). Statin-associated muscle symptoms—Managing the highly intolerant. J Clin Lipidol, 11: 24-33.

4. Backes, J.M., Anzalone, D., Hilleman, D., & Catini, J. (2016). The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis, 15(1), 118.

5. Backes, J. M., Kostoff, M. D., Gibson, C. A., & Ruisinger, J. F. (2016). Statin-Associated Diabetes Mellitus: Review and Clinical Guide. South Med J, 109(3), 167-73.

6. Backes, J. M., Dayspring, T. D., Hoefner, D. M., & Moriarty, P. M. (2015). Hypertriglyceridaemia unresponsive to multiple treatments. BMJ case reports, 2015.

7. Backes, J. M., Ruisinger, J. F., Barnes, B. J., & Moriarty, P. M. (2015). Statin Intolerance and Vitamin D Supplementation: Sunny, but a Few Clouds Remain…. N Am J Med Sci, 7(7), 337-8.

8. Ruisinger, J. F., Gibson, C. A., Backes, J. M., Smith, B. K., Sullivan, D. K., Moriarty, P. M., & Kris-Etherton, P. (2015). Statins and almonds to lower lipoproteins (the STALL Study). J Clin Lipidol, 9(1), 58-64.

9. Backes, J. M., Dayspring, T. D., Hoefner, D. M., Contois, J. H., McConnell, J. P., & Moriarty, P. M. (2014). Identifying Pseudohypertriglyceridemia in Clinical Practice. Clin Lipidol, 9(6), 625-641. (Invited)

10. McGowan, M. P., Moriarty, P. M., & Backes, J. M. (2014). The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. Clin Lipidol, 9(5), 487-503.


11. Backes, J. M., & Howard, P. A. (2014). Krill oil for cardiovascular risk prevention: is it for real? Hosp Pharm, 49(10), 907-12.

12. Backes, J.M., Ruisinger, J.F, Harris, K.A., Harris, W.S, Moriarty, P.M.. (2014). Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil, and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: A Pilot Study. J Glycomics Lipidomics, 4(4), 1-5.

13. Backes, J. M., Dayspring, T., & Moriarty, P. M. (2013). Pseudohypertriglyceridemia - Verifying the Hypertriglyceridemic Patient. J Clin Lipidol, 7, 182-183.

14. Moriarty, P. M., Backes, J. M., Ruisinger, J. F., Schmelzle, K., He, J., & Dutton, J. A. (2013). Apple Pectin for the Reduction of Niacin-Induced Flushing. J Clin Lipidol, 7, 140-146.

15. Backes, J. M., Dayspring, T., Mieras, T., & Moriarty, P. M. (2012). Pseudohypertriglyceridemia: Two Cases of Probably Glycerol Kinase Deficiency. J Clin Lipidol, 6, 469-473.

16. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2012). The High-Dose Rosuvastatin Once Weekly Study (HD-ROWS). J Clin Lipidol, 6, 362-367.

17. Korth, C. E., & Backes, J. M. (2012). Hepatotoxic Effects of Lipid-Altering Agents. US Pharmacist, HS1-HS4.

18. Backes, J. M., Barnes, B., Ruisinger, J. F., & Moriarty, P. M. (2011). A comparison of 25- hydroxyvitamin D levels among those with or without statin-associated myalgias. Atherosclerosis, 218, 247-249.

19. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2011). Modified-Policosanol Does Not Reduce Plasma Lipoproteins in Hyperlipidemic Patients When Used Alone or in Combination with Statin Therapy. Lipids, 46, 923-929.

20. Backes, J. M., Padley, R. J., & Moriarty, P. M. (2011). Important Considerations for Treatment with Dietary Supplement Versus Prescription Niacin Products. Postgrad Med, 123(2), 70-83.

21. Moriarty, P. M., Luyendyk, J. P., Gibson, C. A., Backes, J. M. (2010). Effect of Low Density Lipoprotein Apheresis on Plasma Levels of Apolipoprotein E4. Am J Cardiol, 105, 1585-1587.

22. Ruisinger, J. F., Koerner, J. M., Backes, J. M., & Moriarty, P. M. (2010). Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient. Hosp Pharm, 45, 45-48

23. Shireman, T. I., Reichard, A., Nazir, N., Backes, J., Greiner, K. A. (2010). Quality of diabetes care for adults with developmental disabilities. Disability Health J, 3(3), 179-185.

24. Backes, J. M., & Howard, P. A. (2009). Simvastatin and Amiodarone: Emergence of a Potentially Toxic Interaction. Hosp Pharm, 44, 221-225.


25. Backes, J. M., Howard, P. A., Ruisinger, J. F., & Moriarty, P. M. (2009). Does Simvastatin Cause More Myotoxicity Compared to Other Statins? Ann Pharmacother, 43, 2012-2020.

26. Backes, J. M., Ruisinger, J. F., & Moriarty, P. M. (2009). Sitagliptin-Lovastatin and Possible Rhabdomyolysis: Correlation and Mechanism Unknown. Pharmacotherapy, 29, 174e-175e.

27. Ruisinger, J. F., Backes, J. M., Gibson, C. A., & Moriarty, P. M. (2009). Once-a-Week Rosuvastatin (2.5 to 20 mg) in Patients with a Previous Statin Intolerance. Am J Cardiol, 103, 393-394.

28. Backes, J. M., Venero, C. V., Gibson, C. A., Ruisinger, J. F., Howard, P. A., Thompson, P. D., & Moriarty, P. M. (2008). Effectiveness and Tolerability of Every Other Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance. Ann Pharmacother, 42, 341-346.

29. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2007). Fibrates: what have we learned in the past 40 years? Pharmacotherapy, 27(3), 412-424.

30. Backes, J. M., Moriarty, P. M., Ruisinger, J. F., & Gibson, C. A. (2007). Effects of Once Weekly Rosuvastatin among Patients with a Prior Statin Intolerance. Am J Cardiol, 100, 554-555.

31. Backes, J. M., & Gibson, C. A. (2005). Effect of Lipid-Lowering Drug Therapy on Small-Dense, Low-Density Lipoprotein. Ann Pharmacother, 39, 481-91.

32. Backes, J. M., & Howard, P. A. (2005). Combination Drug Therapy: A Strategy for Aggressive Lipid Modification. Hosp Pharm, 40, 954-62.

33. Backes, J. M., Gibson, C. A., & Howard, P. A. (2005). Optimal Lipid Modification: the Rationale for Combination Therapy. Vasc Health Risk Manag, 1(4), 317-331.

34. Backes, J. M., & Howard, P. A. (2004). C-Reactive Protein as a Marker for Cardiovascular Disease. Hosp Pharm, 39, 735-44.

35. Backes, J. M., Howard, P. A., & Moriarty, P. M. (2004). Role of C-Reactive Protein in Cardiovascular Disease. Ann Pharmacother, 38, 110-18.

36. Backes, J. M., & Howard, P. A. (2003). Association of HMG-CoA Reductase Inhibitors with Neuropathy. Ann Pharmacother, 37, 274-78. (Peer-reviewed/refereed)

37. Moriarty, P. M., & Backes, J. M. (2003). Response to article entitled: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis, 166, 201. Letter (editor reviewed)

38. Backes, J. M., Moriarty, P. M., & Gibson, C. A. (2002). The Effect of Micronized Fenofibrate on Lipid Profiles of Patients Converted from Gemfibrozil. Hosp Pharm, 37, 953-56.

39. Backes, J. M. (2002). Diabetes Mellitus and Cardiovascular Disease. Hosp Pharm, 37, 561-62.


40. Packard, K. A., Backes, J. M., Lenz, T. L., Wurdeman, R. L., Destache, C. J., & Hilleman, D. E. (2002). Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease. Pharmacotherapy, 22, 1527-32.

41. Backes, J. M. (2000). Hyperlipidemia. Hosp Pharm, 35, 551-52.

42. Galt, K., Backes, J. M., & Sondag, L. (2000). Identifying Noncompliance by Combining Refill Audits with Telephone Follow-up. Am J Health Syst Pharm, 57, 219-20.

Author Commentary

1. Backes, J. M. (2009). Invited exclusive author commentary re: Does Simvastatin Cause More

Myotoxicity Compared to Other Statins?. http://www.mdlinx.com/pharmacy/news-article.cfm/2955171 (Invited)

Instructional Materials (Non-peer reviewed)

1. Backes, J. M. (2010). Medications and Oral Health in Children and Youth with Special

Healthcare Needs (1025094). A 2 CE online module focused on the negative oral effects of medications in special needs children. Kansas Train (https://ks.train.org), Kansas Department of Health and Environment.

2. Backes, J. M., Gons, A., & Hanson, N. (2007). Diabetes Medications (2nd ed.). Cray’s Diabetes Center and University of Kansas Medical Center. An educational tool designed to assist practitioners in prescribing, monitoring and identifying oral agents and insulin in the care of persons with diabetes.

3. Backes, J. M. (2001). Diabetes Medications (1st ed.). Cray’s Diabetes Center and University of Kansas Medical Center. An educational tool designed to assist practitioners in prescribing, monitoring and identifying oral agents and insulin in the care of persons with diabetes.

Letter

1. Ruisinger, J. F., Moriarty, P. M., Backes, J. M. (2018). Coenzyme Q10 for statin-associated

myalgia. Am J Health Syst Pharm. (2nd ed., Vol. 75, pp. 14-15). Newsletter Articles

1. Backes, J. M. (2003, 2nd Quarter). The Role of C-Reactive Protein in Cardiovascular Disease.

Heart Monitor, 3.

2. Backes, J. M. (2001, 4th Quarter). Carotid Ultrasonography: A Valuable Tool in Assessing Patient Vascular Risk. Heart Monitor, 1.


Posters (Peer-reviewed/refereed)

1. Ruisinger, J. F., Backes, J. M., & Moriarty, P. M. (2016). Statins Wrongly Accused of Causing Myalgia - Guilty by Association. The National Lipid Association Annual Scientific Sessions. New Orleans, LA

2. Backes, J. M., Ruisinger, J. F., Winefield, R., Singh, R. K., Moriarty, P. M., & Funk, R. S. (2016). Pronounced Variability of Berberine Content Among 15 Commercial Dietary Preparations. The American College of Clinical Pharmacy Annual Meeting, Hollywood, FL

3. Backes, J. M., Ruisinger, J. F., Burkhardt, C. D., & Moriarty, P. M. (2016). Comparison of Patients Prescribed, Self-Reported, and Actual-Intake of Supplemental EPA/DHA. The National Lipid Association Annual Scientific Sessions, New Orleans, LA

4. Backes, J. M., Ruisinger, J. F., Gibson, C. A., Varvel, S., & Moriarty, P. M. (2013). The High-Dose Rosuvastatin Once Weekly Study (HDROWS) – The Effects on Advanced Lipid, Glycemic, and Inflammatory Panels. The American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM

5. Ruisinger, J. F., Backes, J. M., Harris, K., Gibson, C. A., Harris, W., & Moriarty, P. M. (2013). Evaluating the Effects of Krill Oil, Supplemental Fish Oil, and Prescription Fish Oil on Lipoproteins and Gastrointestinal Symptoms – A Randomized Controlled Trial. The American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM

6. Byrd, A., Hare, S., Backes, J. M., Barnes, B., & Ruisinger, J. F. (2013). The impact of a weekly

weigh-in versus nutrition education on body weight indices within an employee wellness program. The American Pharmacists Association Annual Meeting, Los Angeles, CA

7. Schuessler, B., Ruisinger, J. F., Grauer, D. W., Moriarty, P. M., & Backes, J. M. (2012). Comparison of vitamin D dosing regimens in non-obese and obese patients with low vitamin d levels. The American College of Clinical Pharmacy Annual Meeting, Hollywood, FL

8. Moriarty, P. M., Backes, J. M., Ruisinger, J. F., Schmelzle, K., Dutton, J. A., & He, W. (2012). Apple-pectin and its ability to reduce niacin-induced flushing. The European Atherosclerosis Society Congress, Milan, Italy

9. Backes, J. M., Padley, R., Ruisinger, J. F., Acree, L. S., Luoma, J. T., & Moriarty, P. M. (2012). Dietary supplement versus prescription niacin products: Differentiation and important considerations for use in patients with dyslipidemia. The American Pharmacist Association Annual Meeting, New Orleans, LA

10. Moriarty, P. M., Gibson, C. A., Backes, J. M., Eldringhoff, D., Powell, S., & Ruisinger, J. F. (2011). The effect of aggressive cardiovascular treatment on the progression of carotid intima-media thickness: Experience of an Atherosclerosis Prevention Center. The 79th European Atherosclerosis Society Congress, Gothenburg, Sweden


11. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2011). High-Dose Rosuvastatin Once Weekly Study (HD-ROWS). The American College of Cardiology Annual Scientific Session, New Orleans, LA

12. Martin, C., Backes, J. M., & Moriarty, P. M. (2011). Evaluation of associations between body mass index and serum vitamin D levels. The Kansas Council of Health-System Pharmacist Annual Meeting, Lawrence, KS

13. Moriarty, P. M., Luyendyk, J. P., Gibson, C. A., Backes, J. M. (2010). Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein E4. (Invited) The EPS Global 1st International Heart Forum Organizing Committee, Beijing, China

14. Eldringhoff, D. M., Backes, J. M., Ruisinger, J. F., Dutton, J. S., Barnes, B. J., Belmont, J. M., & Moriarty, P. M. (2010). Aggressive treatment of cardiovascular risk factors results in the reduction of atherosclerosis growth as measured by carotid intima-media thickness: experience from an atherosclerosis prevention clinic. The International Academy of Cardiology, 15th World Congress on Heart Disease, Vancouver, BC, Canada

15. Moriarty, P. M., Luyendyk, J. P., Gibson, C. A., Backes, J. M. (2010). Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein E4. The International Academy of Cardiology, 15th World Congress on Heart Disease, Vancouver, BC, Canada

16. Backes, J. M., Greiner, K. A., Ross, R., & Shireman, T. I. (2009). Health Promotion for Kansans with Disabilities: Impact on Diabetes Care Quality. The Cultivating Healthy Kansas Conference, Topeka, KS

17. Greiner, K. A., Backes, J. M., Ross, R., James, A., & Shireman, T. I. (2009). Health Promotion for Kansans with Disabilities: Impact on Cancer Screening. The Cultivating Healthy Kansas Conference, Topeka, KS

18. Shireman, T. I., Greiner, K. A., Backes, J. M., Ross, R., & James, A. (2009). Health Promotion for Kansans with Disabilities: Case Managers’ Assessments. The Cultivating Healthy Kansas Conference, Topeka, KS

19. Shireman, T. I., Greiner, K. A., Backes, J. M., Ross, R., & James, A. (2009). Health Promotion for Kansans with Disabilities: Educational Material. The Cultivating Healthy Kansas Conference, Topeka, KS

20. Shireman, T. I., Ross, R., Greiner, K. A., Backes, J. M., & James, A. (2009). Health Promotion for Kansans with Disabilities. The Cultivating Healthy Kansas Conference, Topeka, KS

21. Shireman, T., James, A., Greiner, A., Backes, J. M., & Ross, R. (2009). Health Promotion for Kansans with Disabilities: Can Targeted Case Managers Effectively Use Health Promotion Information to Improve Health Care Quality? The Academy Health 2009 Annual Research Meeting, Chicago, IL


22. Moriarty, P. M., Gibson, C. A., Backes, J. M., & Luyendyk, J. P. (2009). Apolipoprotein E4 and Its Reduction Following LDL-Apheresis. The XV International Symposium on Atherosclerosis, Boston, MA

23. Moriarty, P. M., Barnes, B. J., Ruisinger, J. F., Backes, J. M. (2009). Assessment of Accelerated Atherosclerosis in Asymptomatic Firemen: The 4 "A"larm Study. The American Heart Association Joint Conference – 49th Cardiovascular Disease Epidemiology and Prevention – and – Nutrition, Physical Activity, and Metabolism, Palm Harbor, FL.

24. Butler, F., Shireman, T., Greiner, A., Backes, J.M., & James, A. (2008). Cancer Screening Among Persons with Developmental and Physical Disabilities Enrolled in Kansas Medicaid. The Kansas Public Health Conference 2008, Topeka, KS

25. Shireman, T., Backes, J.M., Greiner, A., & Ross, R. (2008). Diabetes Care Quality for Kansans

with Physical & Developmental Disabilities. The Kansas Public Health Conference 2008, Topeka, KS

26. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2008). Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance. (Invited) Platform Presentation, 14th World Congress on Heart Disease, The International Academy of Cardiology Annual Scientific Sessions, Toronto, ON, Canada

27. Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2008). Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance. The American College of Clinical Pharmacy Spring Meeting, Phoenix, AZ. Finalist Best Poster Competition – 2nd runner up

28. Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2008). Effects of Policosanol when used in a Lipid-Specialty Clinic. The American College of Clinical Pharmacy Spring Meeting, Phoenix, AZ

29. Moriarty, P. M., Backes, J. M., Ruisinger, J. F., & Gibson, C. A. (2007). Once Weekly Dose of Rosuvastatin for Patients with Prior Statin Intolerance. Platform Presentation, Drugs Affecting Lipid Metabolism (DALM), New York, NY

30. Backes, J. M., Gibson, C. A., Ruisinger, J. F., Hanson, N., Gons, A., & Moriarty, P. M. (2006). Statin therapy effective and better tolerated when administered every other day among patients with previous adverse effects. Platform presentation, American College of Clinical Pharmacy Annual Meeting, St Louis, MO

31. Hanson, N., Backes, J. M., Moriarty, P. M., & Dutton, J. A. (2005). Effect of intima-media thickness measurement on compliance with antihyperlipidemic therapy in a specialty clinic. The American Society of Health-System Pharmacists, Midyear Clinical Meeting and Exhibition, Las Vegas, NV


32. Backes, J. M., Calish, J. S., Gibson, C. A., & Moriarty, P. M. (2005). Fenofibrate impacts a greater number of cardiovascular risk factors compared to atorvastatin in treating mixed dyslipidemia among patients with metabolic syndrome or type 2 diabetes mellitus. The American College of Clinical Pharmacy Spring Meeting, Myrtle Beach, SC

33. Calish, J. S., Backes, J. M., Cohen, T. S., & Moriarty, P. M. (2002). Fenofibrate tablets and its effect on inflammatory markers and blood viscosity. The American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, GA

34. Backes, J. M., Moriarty, P. M., & Gibson, C. A. (2001). The Effect of Micronized Fenofibrate on Lipid Profiles of Patients Converted from Gemfibrozil. The American College of Cardiology 50th Annual Meeting, Orlando, FL

35. Backes, J. M., Chiga, M., Oszko, M., Collene, A., Williams, C., Barnes, J., & Osorio, I. (2000). Comparison of Saliva and Serum Unbound Phenytoin Concentrations in Patients receiving Phenytoin Monotherapy versus Concomitant Phenytoin/Valproic Acid. The American Epilepsy Society 54th Annual Meeting, Los Angeles, CA

36. Backes, J. M., Blaine, P., Kavalir, M., Peltzer, J., Oszko, M., & Osorio, I. (1999). Comparison of Unbound Phenytoin Concentrations in Patients receiving Concomitant Valproic Acid Therapy at Various Concentrations. The American Epilepsy Society 53rd Annual Meeting, Orlando, FL

37. Lacy, M., Metcalf, S., Howard, P., Webb, M., Backes, J. M., & Blaine, P. (1999). Vitamin Supplementation and Natural or Herbal Product Utilization Among Ambulatory Clinic Patients at a University Medical Center. The American College of Clinical Pharmacy Annual Meeting, Kansas City, MO

Invited Presentations/Advisory Boards/Grand Rounds/CE Lectures (Selected out of 180+ programs) National

2018 Advanced Practitioner Expert Advisory Panel. Tarrytown, NY. November 2, 2018 A Closer Look at Unmet Needs Related to Statin Therapy. Dyslipidemia Lectures presented to Pharmacists, Cardiologists, Lipidologists, Nurse Practitioners, and Physician Assistants on six occasions, Rogers, AR; Nashville, TN; Cape Girardeau, MO; Martinsville, IN and Arlington, TX. 2017-2018 Clinical Insights on Applications of Non-Statin Therapies to Guide Patient Selection and Medication Management in Hypercholesterolemia. A CE program - Pharmacists, Fort Lauderdale, FL. August 4th, 2017. Co-presented with Sheila Stadler, PharmD and Jennifer Robinson, MD Kowa Steering Committee. Dallas, TX. April 1, 2017 The New Era of Cholesterol Management. A CE program to Pharmacists at the Tom D. Rowe 65th Annual Pharmacy Lectures, Ann Arbor, MI. October 21st, 2016 Praluent Q4 Advisory Board. Atlanta, GA. December 2, 2016


AstraZeneca Medical Affairs Advisory Board. Coral Gables, FL. July 22, 2016 Getting your patients on board with risk factors and new approaches for hypercholesterolemia care. A CE program - Pharmacists, Fort Lauderdale, FL. August 28th, 2015. Co-presented with Joe Sasseen, PharmD Advancing Knowledge of Hypertriglyceridemia. APhA National Meeting 2015, San Diego, CA. March 28, 2015 EPANOVA Speaker Training. Speaker Training for EPANOVA - sponsored by Astra Zeneca., San Francisco, CA. June 12, 2014 Antisense Therapy and FH: Mechanisms of Action. A National Lipid Association Symposium: Clinical Advancements in the Management of Familial Hypercholesterolemia, Las Vegas, NV. May 31st and October 2nd, 2013 Lipid Leaders: BE ONE for Your Patients. A 2-day lipid CE conference focused on patient care and MTM, Des Moines, IA. April 18-19th, 2013. Co-presented with Joe Sasseen, PharmD and CoraLynn Trewet, PharmD Livalo: A Clinical Update. A CE presentation to D.O. Physicians at the Annual American College of Osteopathic Physicians Conference, Orlando, FL. July 28th, 2011 Importance of Treating Patients with Low HDL-C. Presented to Pharmacists, Physicians, Nurse Practitioners, and Physician Assistants on six occasions, Leawood, KS; Kansas City, MO; North Kansas City, MO; Wauwatosa, WI; Libertyville, IL; Houston, TX. 2010 Clinical and Economic Considerations of Statin Formulary Management within Managed Care Environments. A CE program to Primary Care Practitioners, San Diego, CA. April 5th, 2007 The Role of the Pharmacist in the Medical Management of Dyslipidemia Patients. A CE presentation to Pharmacists, Long Island, NY October 24, 2005; Valdosta, GA May 18, 2006; Houston, TX December 12, 2006 An Update on Lipids. A CE Program for Physicians and Allied Health Professionals. Annual Cardiology Update Conference - American Heart Association and Sierra Providence Health Network, El Paso, TX. February 11th, 2005 Management of Dyslipidemia in the 21st Century: Meeting the Challenge and Optimizing Patient Care. A CE Program to Pharmacists, Physician Assistants and Nurse Practitioners, San Diego, CA. September 5, 2004; Long Island, NY. September 7, 2004 Treatment of the Atherogenic Lipid Profile. A CE presentation to Pharmacist and Technicians at the Central Minnesota Society of Health-Systems Pharmacists monthly meeting, Minneapolis, MN. January 13, 2004 A Focus on HDL-C and Triglycerides. 2000 Diabetes Management Speakers Bureau (Parke-Davis and Designing Solutions), Carlsbad, CA. March 5, 2000


Heart Care Partnership. A symposium on post myocardial infarction protocol development, Torrey Pines, CA. June 28, 1998

Regional

Omega-3 Fatty Acids (Fish Oil) and Cardiovascular Risk. A CE Presentation to Pharmacists of the Southwest Iowa Pharmacists Association, Omaha, NE. April 19th, 2018. Co-presented with Dan Hilleman, PharmD Understanding High Triglycerides. Northwest Arkansas District 7 Pharmacists, Fort Smith, AR. November 11th, 2014 Life in a Lipid-Specialty Clinic. Keynote address for the 2012 Greater Omaha Pharmacy Residency Banquet, Omaha, NE. June 14, 2012 Clinical and Economic Considerations of Statin Formulary Management within Managed Care Environments. A CE program to Primary Care Practitioners, St. Louis, MO. March 29, 2007 Drug Therapy for Mixed Dyslipidemia. A presentation to District Managers of Abbott Laboratories, Oak Brook, IL. November 30, 2006 Lipid Management: Improving Patient Outcomes. A CE presentation to Nurse Practitioners, Nurses and Physician Assistants, West Des Moines, IA. August 22, 2000 New Developments and Treatment Options in Managing Dyslipidemias. A CE Presentation to Pharmacists at the Mid-America and Gateway Colleges of Clinical Pharmacy joint meeting, Lake of the Ozarks, MO. August 4th, 2000 The Pharmacist’s Role in Managing Diabetes. A CE Presentation to Physicians, Nurses, Dieticians and Pharmacist-Regional Symposium on Diabetes Mellitus, Kansas City, MO. April 9th, 1999

State

An Overview of Lipid-Altering Agents...the Old and the New. A CE program to Advanced Practice Nurses at the "Advanced Practice Providers Partnering Today for a Better Tomorrow.", Kansas City, KS. November 11th, 2016 Start a Statin and then what? An update on dyslipidemia management. KCHP/MSHP 2016 Annual Meeting, Overland Park, KS. April 22nd, 2016. Co-presented with Matt Kostoff, PharmD A Clinical Approach to the ACC/AHA Cholesterol Guidelines - CE program. 2014 KPhA Annual Meeting, Lawrence, KS. September 5th, 2014 The Role of Combination Therapy in Mixed Dyslipidemia. Presentation to Pharmacists, Springfield, MO. February 17, 2011 What’s New in Type 2 DM? KPhA 2010 Fall Conference, Lawrence, KS. September 24th, 2010


Managing Dyslipidemia Associated with Insulin Resistance. A CE presentation to Dermatologists, Kansas State Dermatology Meeting, Wichita, KS. August 26th, 2006 Managing Lipids with Statin and Nonstatin Medications. A CE presentation at the "Annual Four State Nurses' Conference". McPherson Nursing Center, Pittsburg, KS. October 27, 2005 How Low Should You Go? The LDL Lowering Dilemma. A CE Program for Pharmacists, Pharmacy Technicians and Pharmacy Students. 2005 Iowa Pharmacy Association's Education Expo, Des Moines, IA. January 22nd, 2005 Treatment Approaches for Mixed Dyslipidemia. A presentation to Internal Medicine Physicians. Newman Regional Health Hospital, Emporia, KS. January 22, 2003 Lipid Management: Improving Patient Outcomes and ATP III Update. A CE presentation to Hospital Pharmacists, Missouri Society of Health-System Pharmacists Fall Meeting, Columbia, MO. October 20th, 2001 The Management of Dyslipidemias. A Presentation to Physicians and Nurses of the Whiteman Air Force Base, Whiteman Air Force Base, MO. October 20, 1999 Obesity and It’s Complications. A CE Presentation to Pharmacists, Pharmacy Students and Pharmacy Technicians. Kansas Pharmacists 119th Annual Meeting. Double Tree Hotel, Overland Park, KS. September 24th, 1999 The Treatment of Obesity and the Associated Comorbidities. Presentation to Pharmacists, Physician Assistants and Nurse Practitioners-The Northeast Kansas Pharmacists Association, Hiawatha, KS. April 22, 1999 Management of Dyslipidemias. Presentation to out-state Physicians, via interactive television, University of Kansas Medical Center. February 26, 1999 Smoking Use and Cessation: Role of the Health Care Provider. A CE Program for Pharmacists, Wichita, KS. August 26th, 1998. Co-presented with Larry Davidow, PhD and Jack Fincham, PhD

Local

Everything You Wanted to Know about Statins....and More! A CE program to Health Care Providers. Johnson County Community College, Overland Park, KS. June 28th, 2017 Therapeutic Options for Difficult to Treat Dyslipidemic Patients. A Lipid Forum involving local Lipidologists. Kansas City, MO. May 11, 2016. Co-presented with Patrick Moriarty, MD Can LDL-C go lower? A Roundtable Lipid Forum involving local Clinical Pharmacists, Kansas City, MO. November 12, 2015 Lipid Updates from the ACC Annual Scientific Sessions. A Roundtable Lipid Forum involving local Lipidologists. Kansas City, MO. April 21, 2015. Co-presented with Patrick Moriarty, MD


A Pharmacy Perspective on the ACC/AHA Cholesterol Guidelines. (CE). Greater Kansas City Health System Pharmacists Monthly Meeting., Kansas City, MO. September 18th, 2014 Updates in Clinical Research. Internal Medicine Grand Rounds (CE). University of Kansas Medical Center. August 14th, 2013. Co-presented with Patrick Moriarty, MD. An Overview of Diabetes-related Medications. Presentation to Certified Diabetes Educators, The Kansas City Regional Association of Diabetes Educators, Kansas City, MO. November 8, 2011. Co-presented with C. Gilbert, ARNP. Interdisciplinary Research in a Clinical Setting: From Fruits to Nuts, alternative methods in treating atherosclerosis and dyslipidemia. Internal Medicine Grand Rounds (CE). University of Kansas Medical Center. August 10th, 2011. Co-presented with Patrick Moriarty, MD and Janelle Ruisinger, PharmD Interdisciplinary Research in a Clinical Setting: The Use of Multiple Disciplines in The Atherosclerosis and LDL-apheresis Center. Internal Medicine Grand Rounds (CE). University of Kansas Medical Center. January 13th, 2011. Co-presented with Patrick Moriarty, MD Everything You Need to Know About Lipids in 1 Hour. A CE program to Physicians, PA’s, and NPs. Topeka Cardiovascular Conference, Topeka, KS. December 11, 2008 New Developments in Treating Dyslipidemia. Annual Branson Geriatric Conference. A CE program to Primary Care Physicians. University of Kansas Area Health Education Center, Branson, MO. August 4th, 2007 New Developments in Treating Dyslipidemia. Grand Rounds – St. Luke’s South. A CE program to Primary Care Physicians and Cardiologists, Overland Park, KS. April 5, 2007 New Developments in Treating Dyslipidemia. A CE program to Physicians. University of Kansas Area Health Education Center, Coffeyville, KS. January 23, 2007 Enhancing Adherence to Prescribed Medications. Physicians and Nurses. Fairmont Hotel, Kansas City, MO. December 8, 2005 An Overview of Medications to Treat Diabetes Mellitus. Presentation to M1 Students - Health Promotion and Disease Prevention Course. University of Kansas School of Medicine, Kansas City, KS. November 12, 2003 The Pharmacologic Management of Seizures. Presentation to the Neurology Medical Residents of the University of Kansas Medical Center, Kansas City, KS. October 22, 1999 Looking Beyond LDL in the Management of Dyslipidemia. Presentation to Physicians, Medical Residents and Medical Students. The University of Health Sciences College of Osteopathic Medicine, Kansas City, MO. September 10, 1999


Research Funding/Support University of Kansas

Commission

Employee Leasing Agreement. Kansas University Physicians Inc. (KUPI) and University of Kansas Physicians (UKP), 10% salary support (January 2013 - Present). Renewed Annually.

Externally-Funded Grants

*Indicates Industry-sponsored studies (as a multicenter study site) **Indicates partial support from KU General Research Fund

Funded

*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis. Regeneron Pharmeceuticals, Inc. $ - pending (2018 – Present)

*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD). Akcea Therapeutics, Inc. $ - pending (2018 – Present)

*Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), Ruisinger, J. F. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy. Regeneron Pharmaceuticals, Inc. $ - pending (2018 – Present)

*Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator), Ruisinger, J. F. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD). Ionis Pharmaceuticals, Inc., $550,000 (2017 – Present)

*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC -1002) On the Occurrence of Major Cardiovascular Events in Patients With, or At High Risk for, Cardiovascular Disease Who are Statin Intolerant (CLEAR-OUTCOMES). Esperion Therapeutics, $ - pending (2017 – Present) Sullivan D.K, (Co-principal), Burns, J.M. (Co-principal), Backes, J. M. (Co-Investigator), Gibson, C.A., Taylor, M., Lee, J., Mahnken, J., Vidoni, E., Lee, P., Choi, I.-Y., Burns, J. Nutrition Interventions for Cognitive Enhancements (NICE). National Institute on Aging 1R01AG060157-01 Direct Costs - $3,692,744; 4% salary support; (November 2018 – October 2023).


*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease. Amgen, $160,236 (2016 - Present). *Moriarty, P. M. (Principal), Backes, J. M. A Randomized Double-Blind Placebo Controlled Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post Myocardial Infarction Patients With Elevated hsCRP (CANTOS). Novartis, $136,583 (2012 - Present). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment. Amgen, $19,040 (2016 - 2017). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Multicenter, Controlled, Open-Label Extension Study to Assess the Long-term Safety and Efficacy of AMG145 (OSLER-2). Amgen, $39,798 (2015 - 2018). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia. Ionis, $76,634 (2015 – 2017). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects (GAUSS-3). Amgen, $175,188 (January 2014 - 2018). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732, & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Sanofi, $105,219 (January 2014 - 2017). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Study to Evaluate the Effect of SAR236553 REGN727 on the Occurrence of Cardiovascular Patients Who Have Recently Experienced and Acute Coronary Syndrome (ODYSSEY-OUTCOMES). Regeneron, $257,725 (March 2013 - 2017). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins. Regeneron, $501,636 (January 2013 - 2017). Backes, J. M. (Co-Principal), Gibson, C. A. (Co-Principal), Lee, J. Identifying Perceptions and Attitudes regarding Statin-Associated Diabetes Mellitus. Investigator-initiated trial. Kowa Pharmaceuticals $74,500, 3% salary support, (2016 - 2018).


*Moriarty, P.M. (Principal), Ruisinger, J.F., Backes, J.M. (Co-Investigator). A phase 3, double-blind, double-dummy, randomized, placebo and active controlled, parallel-group study to assess the efficacy, safety and tolerability of PF-04950615 in subjects with dyslipidemia who are intolerant to statins., Pfizer, $50,445 (2015 - 2016). *Moriarty, P.M. (Principal), Ruisinger, J.F., Backes, J.M. (Co-Investigator). A Randomized, Open-Label Crossover Study to Compare the relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women with a History of Pancreatitis., Omthera Pharm, $39,120 (2015 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Alirocumab Expanded Access Program for the treatment of patients with Severe Hypercholsterolemia not Controlled with Maximal Tolerated Dose of Lipid-Lowering Therapy Administered According to Standard of Care. Sanofi, $28,650 (2015 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety and Tolerability of Bocozimab in Reducing the occurrence of Major Cardiovascular Events in High Risk Subjects B1481038. Pfizer, $190,947 (2015 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome. Ionis Pharm, $24,745 (2015 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A phase 3 double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, long-term safety and tolerability of PF-04950615 in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events., Pfizer, $89,930 (2014 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia (ODYSSEY CHOICE). Regeneron, $72,455 (2014 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Study Assessing the Impact of Additional LDL Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease (FOURIER). Amgen, $688,407 (2012 - 2016). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of (Study Drug) in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol., Genzyme, $63,874 (2011 - 2016).


*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A Randomized, Double-blind, Placebo Controlled study to Assess the Safety and Efficacy of CAT-2054 in Combination with Atorvastatin in Patients with Hypercholesterolemia. Catabasis, $16,000 (January 2016 - July 2016). *Moriarty, P. M. (Principal), Backes, J. M. (Co-Investigator). A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipid apheresis therapy (ESCAPE). Amgen, $157,639 (2014 - 2015). Moriarty, PM, (Principal) Backes, J. M. (Co-Investigator) A double-blind, randomized Study, comparing the effects of Pitavastatin, Atorvastatin, and Rosuvastatin on plasma levels of CoQ10. Investigator-initiated trial. Kowa Pharmaceuticals $776,000, 4% salary support (2011 - 2013). Moriarty, PM, (Principal) Ruisinger, JF, Backes, J. M. (Co-Investigator) Alternative Options to Minimize Niacin-Induced Flushing-A Pilot Study. Investigator-initiated trial. Abbott Labs $174,123, 3% salary support (2008 - 2009). **Ruisinger, J.F. (Principal), Gibson, C.A., Backes, J. M. (Co-Investigator), Smith, B.K., Sullivan, D.K., Moriarty, P.M., Kris-Etherton, P. Efficacy of Almonds Added to Chronic Statin Therapy. General Research Fund University of Kansas School of Pharmacy and Almond Board of California [$51,000 total: $15,000 GRF + $36,000 Almond Board of California, 3% salary support] (2007 - 2009). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). The CRESCENDO Study (rimonabant): A randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of study drug for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. Sanofi-Aventis $270,000 (2006 - 2008). **Backes, J. M. (Principal), Gibson, C.A., Ruisinger, J.F., Moriarty, P.M. Safety and Efficacy of Policosanol added to Chronic Statin Therapy: a Pilot Study. General Research Fund University of Kansas School of Pharmacy and Marcor [$73,608 total: $20,000 GRF + $53,607.50 Marcor, 7% salary support] (2006 – 2007). Shireman, T.I. (Principal), Reichard, A. Nazir, N., Backes, J. M. (Co-Investigator), Greiner, K.A. Using Case Managers to Improve Preventive Health Care in the Disabled Medicaid Population. Kansas Foundation for Medical Care $303,784, 10% salary support. (2007 – 2009). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A double-blind, randomized study to evaluate the efficacy and safety of TAK-475 100 mg or placebo when co-administered with high dose statin therapy in subjects with primary hypercholesterolemia. Takeda $23,502 (2006 - 2007). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). A double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50 mg, 100 mg or placebo when co-administered with rosuvastatin (10 or 20 mg) in subjects with primary hypercholesterolemia. Takeda $7,840 (2006 - 2007).


*Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Open label, dose-escalating efficacy and safety study of study drug (MTP-Inhibitor) at doses ranging from 10 mg to 40 mg daily in patients with hypertriglyceridemia on maximal, concurrent triglyceride-lowering therapy. Pharmaco Investments, $16,780 (2005 – 2006). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). Year long, double-blind, randomized, dose-escalating efficacy and safety study of study drug (MTP-Inhibitor) at doses ranging from 10 mg up to 40 mg, compared with placebo in patients with heterozygous familial hypercholesterolemia on maximal, tolerable, concurrent lipid-lowering therapy. Pharmaco $21,855 (2004 – 2005). *Moriarty, P. M. (Principal), Ruisinger, J. F., Backes, J. M. (Co-Investigator). An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia (OCEANS). Kos Pharmaceuticals, $17,004 (2004 – 2005). Backes, J. M. (Co-Principal), Moriarty, P. M. (Co-principal). Extended-Release Niacin and Its Effect on Inflammatory Markers, Proinsulin and Blood Viscosity. Investigator-initiated trial. Kos Pharmaceuticals $11,087, 2% salary support (2003 - 2004). Backes, J. M. (Principal), Moriarty, P. M., Ruisinger, J. F. Fenofibrate tablets and Its Effect on Inflammatory Markers and Blood Viscosity. Investigator-initiated trial. Abbott Laboratories $79,425, 15% salary support (2002 - 2004).

Not Funded

Backes, J. M. (Co-Principal), Gibson, C. A. (Co-Principal), Rasu, R., & Lee, J. Exploring Critical Factors Related to Statin Nonadherence. National Heart Lung and Blood Institute 1R21HL130916-01, Direct Costs - $427,555; 8% salary support, (2016 - 2017). Backes, J. M. (Principal), Gibson, C. A., Ruisinger, J. F., Moriarty, P. M. The impact of less frequent statin dosing on critical clinical barriers. Patient Centered Outcomes Research Institute (PCORI), Direct Costs - $1,925,400; 60% salary support, (2014 - 2017). Backes, J. M. (Principal), Moriarty, P. M., Ruisinger, J. F. The impact of less frequent statin dosing on common adverse events. American Heart Association Grant-in-Aid, Direct Costs - $143,000; 9% salary support, (2014 - 2016). Backes, J. M. (Principal), Gibson, C. A., Lee, J., & Rasu, R. The Impact of Once-Weekly Statin Dosing on Adherence Parameters and Glycemic Indices (LOI)., Kansas City Life Sciences Institute, Blue KC Outcomes Research Grant Opportunity, Direct Costs - $50,000; 4% salary support, (2015 - 2016). Backes, J. M. (Principal), Moriarty, P. M., Ruisinger, J. F. The impact of less frequent statin dosing on common adverse events. American Heart Association Grant-in-Aid, Direct Costs - $143,000; 10% salary support, (2013 - 2015).


Backes, J. M. (Principal), Gibson, C. A., Ruisinger, J. F., Moriarty, P. M. The impact of less frequent statin dosing on critical clinical barriers. Patient Centered Outcomes Research Institute (PCORI), Direct Costs - $1,592,974; 40% salary support, (2013 - 2016). Backes, J. M. (Principal), Gibson, C. A., Ruisinger, J. F., Moriarty, P. M. Evaluating the effects of amiodarone on key pitavastatin pharmacokinetic parameters. Investigator-initiated trial. Kowa Pharmaceuticals, Direct Costs - $227,500; 10% salary support (2014 - 2015). Backes, J. M. (Principal). Gibson, C. A., Ruisinger, J. F., Moriarty, P. M. Pantethine/Niacin Combination Therapy. Endurance Products Co/ Kyowa Hakko USA. Investigator-initiated trial. Direct Costs - $473,722; 10% salary support (2011 – 2012). Gibson, C. A., (Principal), Backes, J. M. (Co-investigator). Overweight and Obesity Training Program for Safety Net Clinic Providers. Health Care Foundation of Greater Kansas City, Direct Costs - $147,203; 3% salary support (2008 - 2010). Moriarty, P. M., (Principal), Backes, J. M. (Co-investigator). Effect of Pioglitazone on Vascular Function, as measured by Blood Pressure changes, and its Association to changes in Hemorrheology among Patients with Metabolic Syndrome. Investigator-initiated trial. Takeda, Direct Costs - $230,480; 5% salary support (2006 – 2007). Moriarty, P. M., (Principal), Backes, J. M. (Co-investigator). Effect of Rosiglitazone on Blood Viscosity and Inflammatory Markers in Patients with Metabolic Syndrome. Investigator-initiated trial. Glaxo Smith Kline, Direct Costs - $230,480; 5% salary support, (2006 – 2007). Gibson, C. A (Principal), Vacek, J., Backes, J. M. (Co-investigator). The Effects of Lipid-lowering Therapy on Low-Density Lipoprotein Subfractions. 1RO1DK073931-01, National Heart Lung and Blood Institute, Direct Costs - $688,657; 10% salary support, (2005 – 2008). Backes, J. M. (Principal), Moriarty, P. M. Colesevelam and Its Effect on Inflammatory Markers. Investigator-initiated trial. Sankyo Pharma, Direct Costs - $37,825; 10% salary support, (2001 –2002).

General Research Fund (without additional external funding support) Funded

Backes, J. M. (Principal), Ruisinger, J.F., Harris, K.A., Gibson, C.A., Harris, W.S., Moriarty, P.M. Evaluating the Tolerability and Effects of Krill Oil on Major Lipoproteins and the Omega-3 Index: A Pilot Study. General Research Fund University of Kansas School of Pharmacy. $30,000 (2012 - 2014). Ruisinger, J.F. (Principal), Backes, J.M. (Co-investigator), Harris, K.A., Gibson, C.A., Harris, W.S., Moriarty, P.M. Comparing the Tolerability and Effects of Rx and Supplemental Fish Oil on Major Lipoproteins and the Omega-3 Index: A Pilot Study. General Research Fund University of Kansas School of Pharmacy $7,000 (2010 - 2012).


Internal Award Funded

Backes, J. M. (Principal), Gibson, C. A., Mount, R., Lee, J., Ruisinger, J. F., Moriarty, P. M. Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study. Internal funds from employee leasing agreement, $38,891 (December 2018 - present). Backes, J. M. (Principal), Gibson, C. A., Ruisinger, J. F., Moriarty, P. M. High-Dose Once Weekly Rosuvastatin Study (HD-ROWS). $16,622 (2009 - 2010).

Research/Non-Funded Projects

Backes, J. M. (Principal), Ruisinger, J. F., Melton, B. L., Burkhardt, C., Moriarty, P. M. Dosing challenges involving supplemental fish oil - a pilot study. KUMC - Atherosclerosis and LDL-Apheresis Center (2015 - 2017)


INSTRUCTION KU Courses Taught (all KU School of Pharmacy unless otherwise noted)

1998 – present: PHPR 662 Pharmacotherapy II (formerly PHPR 647)

Intro to CV/Hypertension, Coronary Heart Disease/Dyslipidemia, Seizure Disorders (20 contact hours)

1998 - present: PHPR 663 Pharmacotherapy III (formerly taught in PHPR 647) Diabetes mellitus (15 contact hours) 2015 - present: PHPR 670 Clinical Assessment (~15 contact hours) 2015 – present: PHPR 541, PHPR 542, PHPR 543 Foundations of Interprofessional Collaboration I - III (12 contact hours) 2007, 2015: PHPR 635 Problems in Pharmacy Practice (30 contact hours) 1998 – 2010: PHAR 693 Clinical Pharmacokinetics Phenytoin Pharmacokinetics, Anticonvulsant Overview (3 contact hours) 1999 – 2000: PHPR 646 and 647 Pharmacotherapy I and II

ADD/ADHD, Depressive Disorders, Bipolar Disorder, Parkinson’s Disease, Headache Disorders (9 contact hours)

1999 – 2000: PHPR 625, 627, 628 Pharmacotherapy; PHCH 694 Clinical Kinetics

KU SOP Nontraditional PharmD Program Diabetes Mellitus, Dyslipidemias, Hypertension, Seizure Disorders, Parkinson’s Disease, Phenytoin Pharmacokinetics (30 contact hours)

1998 – 2000: PHPR 503 Pharmacy Practice III Smoking Cessation (1 contact hour)

1998 – 2016: PHRM 850 Medical Pharmacology (KU School of Medicine) Rx Writing (4 contact hours) 1998 – 2014: NRSG 813 Applied Drug Therapy (KU School of Nursing) Lipid Disorders, Diabetes Mellitus (6 contact hours)

Experiential Teaching/Master’s Thesis

University of Kansas

Advanced Pharmacy Practice Experience Rotation Preceptor/Co-preceptor 24 students annually (1998 - 2010) 20 students annually (2011 - 2016) 12 students annually (2017 – Present)


KUMC Pharmacy Residency Programs (Community Pharmacy, Hospital, Drug Information) Longitudinal and monthly Rotation Preceptor/Co-preceptor 1 - 3 PGY1/PGY2 Pharmacy residents annually (1998 – Present)

University of Nebraska Medical Center

Advanced Pharmacy Practice Experience Rotation Preceptor/Co-preceptor 12 students annually (1995 - 1998)

Master's Thesis Committees/Resident Research Projects

8 PGY1/PGY2 pharmacy residents (2000 - 2014)

Academic Student Advising

10 undergraduate students advised (2012 - 2016)


SERVICE University Service

University of Kansas Medical Center

Liaison KU/KUMC Campus Parking/Facilities/Building. (Fall 2016 - Present)

Member

Joint CE Program Development Committee. (Fall 2017 - Present) CIPER Assessment & Scholarship Committee. (Fall 2016 - Present) Conflict of Interest Committee. (Fall 2016 - Present) Wescoe Building Advisory Committee. (Fall 2016 - Present) s-EHR Steering Committee. (Fall 2016 – Spring 2018) Community Health Project - Advisory Board. (Fall 2016 – Fall 2017) Cray Diabetes Center Advisory Board. (1998 - 2016) Interview Panel for Pharmacy Residents. (1998 - 2008) Pharmacy Resident Mentoring Program. (1998 - 2006) Planning Committee - CME/CNE Lipid CE Program. (Fall 2003)

University of Nebraska Medical Center

Member Interview Panel for New Pharmacists and Technicians. (1994 - 1998) Interview Panel for Pharmacy Residents. (1997) Phamis Problem List Task Force. (1997) Ambulatory Pharmaceutical Care Advisory Team. (1996 - 1997)

School Service


Chair Seminar Series Committee (Fall 2018 – Present) Academic and Professional Conduct Committee. (Fall 2016 - Present) Progress Toward Promotion Review Committee (Nguyen). (Spring 2019) Promotion +/- Tenure Review Committee (Ruisinger). (Fall 2015 - Spring 2016) Faculty Executive Committee. (Fall 2014 - Fall 2015) Post Tenure Review Committee (Howard). (Spring 2015) Faculty Search Committee - PHPR Tenure-Track positions. (Fall 2012 - Summer 2014) Faculty Search Committee - PHPR Tenure-Track position. (Spring 1999 - Summer 1999)

Member

Admissions Committee. (2010 – 2014; Fall 2016 - Present) Dean's Administrative Committee. (Fall 2016 - Present) Residency Club. (Fall 2016 - Present) Faculty Executive Committee. (Fall 2012 - Present) Promotion +/- Tenure Review Committee (Melton). (Fall 2018 - Spring 2019)


Promotion +/- Tenure Review Committee (Moeller). (Fall 2017 - Spring 2018) Progress Toward Tenure Review Committee (Funk). (Spring 2017) Faculty Search Committee - PHPR Tenure-Track positions. (Fall 2016 - Spring 2017) Departmental 5-yr Chair Review Committee (Henry). (Spring 2016) Dr. Jeremy Matchett Excellence in Pharmacy Award Panel. (Spring 2016) Progress Toward Tenure Review Committee (Melton). (Spring 2016) Departmental 5-yr Chair Review Committee (Schoneich). (Fall 2014 - Spring 2015) Experiential Rotation Evaluation Committee, NTPD. (2001 - 2011) Assessment and Outcomes Committee. (Fall 2007 - Fall 2010) Planning Committee-CE Program, Lipid Management - A Curricular-Based Course for

Pharmacists, School of Pharmacy Continuing Education Office. (Fall 2004 - Fall 2009) Academic and Professional Conduct Committee. (Fall 2006 - Summer 2008) Search Committee-Chairman Department of Pharmacy Practice. (Fall 2005 - Spring 2008)

Department Service


Pharmacy Practice Chair

Professional Record Online (PRO) - Departmental Coordinator (2010 - 2018) Faculty Orientation, Mentoring, and Development (FOMD) Committee (2014 - 2015)

FOMD Subcommittee - Establishing a Clinical Practice FOMD Subcommittee - Promotion +/- Tenure FOMD Subcommittee - Research and Scholarship

Member

FOMD Subcommittee - History and Organization (2014 - 2015) FOMD Subcommittee - Teaching (2014 - 2015) Pharmacy Practice Faculty Mentoring Policy Committee (Fall 2014) Adjunct Faculty Appointment Committee (2008 - 2014) Strategic Planning Committees 3 (2009 - 2013) PHPR Tenure Track P+T Guidelines Revision Committee (Fall 2011) PHPR Clinical Track Promotion Guidelines Revision Committee (Spring 2011) Strategic Planning Committees 1 (2009 - 2011)

Professional Service

International

Reviewer, Book ACCP Pharmacist Guide to Lipid Management. (Summer 2013 - Winter 2013)

Reviewer, Journal Article

Annals of Medicine Annals of Pharmacotherapy Drug in R & D European Journal of Internal Medicine Expert Opinion on Drug Safety


Future Cardiology Hospital Pharmacy International Scholarly Research Notices Journal of Clinical Lipidology Journal of Clinical Pharmacology Pharmacotherapy Postgraduate Medicine The American Journal of Managed Care Vascular Health and Risk Management

National

American College of Clinical Pharmacy. School of Pharmacy Liaison (2005 - 2016) State

Board Member Government Affairs Committee, KPhA (Fall 2018 – Present) Drug Utilization Review Board, Kansas Department of Social and Rehabilitation Services.

Academic Pharmacist (2000 – 2003; 2014 - Present)

Professional Memberships Kansas Pharmacists Association (KPhA) (2016 - Present) American Association of Colleges of Pharmacy (2000, 2011 - Present) National Lipid Association (2006 - Present) American College of Clinical Pharmacy (1998 - Present) Mid-America College of Clinical Pharmacy (1998 - 2004)

Public Service

Local Advisory Board Member, Johnson County Community College Pharmacy Technician Program. Johnson County Community College, Overland Park, KS (2012 - Present)

Service-Other Levels

Volunteer, Monthly Meal Preparations, Shalom House (Men’s Shelter), Kansas City, KS (2017 – Present)

Participant, Community Cholesterol Screenings, Shepherd Center, Kansas City, KS (1998 - 2004) Participant, Professional Shadowing Program, University of Nebraska Medical Center College of

Pharmacy and Kansas University Medical Center. (1995 - 1998)


Service Presentations Backes, J. M. An Overview of Diabetes Mellitus and Hypertension. Presented annually at the KU

Pharmacy Summer Camp, Lawrence, KS. Backes, J. M. Diabetes Medications. Presentation to patients of the Cray Diabetes Center, University

of Kansas (presented ~15 times/year; 1998 - 2017). Consulting

WriteHealth LLC, Consultant (Fall 2017). Individualizing Treatment with Statin Therapy - serving as writer and content developer of review article – J Fam Pract

WriteHealth LLC, Consultant (Spring 2016). Research Perspectives: Innovations and Implications of New LDL-lowering Strategies. Developed online CE program involving PCSK9 inhibitor therapies - serving as writer and facilitator.

WriteHealth LLC, Consultant (February 20, 2015 - March 9, 2015). Freelance writing - developed review article outline for Treatment and Management of Pediatric Familial Hypercholesterolemia for publication - J Fam Pract

References to My Work

"Zocor warning probably shouldn’t come as a surprise" Los Angeles Times. (June 9, 2011)

"Firefighters Have Narrower-Than-Normal Arteries, Study Finds. Experts cite smoke, eating

habits and sleep patterns as potential causes" U.S. News and World Report; HealthDay News; Health Central; her News; MSN. (March 13-17, 2009)

Interviews

"Once Weekly Statin Therapy Effective and Well-Tolerated in Patients with a Prior Statin Intolerance" Internal Medicine News, Vol. 41, pg. 16. (2008)

Invited Platform Presentation, 14th World Congress on Heart Disease, The International Academy of Cardiology Annual Scientific Sessions, July 27th, 2008, Toronto, ON, CA; Interviewed by Mitchel L. Zoler

"Statin therapy effective and better tolerated when administered every other day among patients with previous adverse effects" Pharmacy Practice News, Vol. 33, pg. 11. (2006)

Platform Presentation, American College of Clinical Pharmacy Annual Meeting, October 27th, 2006, St. Louis, MO; Interviewed by Jan Greene

"Micronized Fenofibrate Outperforms Gemfibrozil" Internal Medicine News, Vol. 34, pg. 33. (2001)

American College of Cardiology 50th Annual Meeting, Orlando, FL, March 2001 Interviewed by Mitchel L. Zoler (Philadelphia Bureau)

Documents

JAMES M. BACKES, PHARM.D. Curriculum Vitaeprovost.ku.edu/.../files/docs/candidate-cvs/backes-resume.pdf · 2016 – Present: Associate Dean for Clinical and Medical Center Affairs